Using smart nanoparticles to deliver a natural cancer-fighting drug for metastatic colorectal cancer.
"SMART" nanoparticle delivery of veratridine overcomes clinical challenges in metastatic colorectal cancer.
This study is testing a new way to deliver a natural anti-cancer drug directly to metastatic colorectal cancer cells using tiny particles, which could make the treatment work better and cause fewer side effects for patients with advanced CRC.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Dakota NIH-funded |
| Lab location | 1 site (Vermillion, United States) |
| Project ID | NIH-11077358 on NIH RePORTER |
What this research studies
This research focuses on developing innovative nanoparticles that can deliver a natural anti-cancer drug, veratridine, directly to metastatic colorectal cancer (CRC) cells. The approach aims to enhance the effectiveness of the treatment while minimizing side effects on healthy cells. By utilizing smart technology, these nanoparticles will release the drug specifically at tumor sites, which could improve treatment outcomes for patients with advanced CRC. The research involves both laboratory and animal testing to evaluate the effectiveness and safety of this targeted delivery method.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer who have not responded well to conventional treatments.
Not a fit: Patients with early-stage colorectal cancer or those whose cancer has not metastasized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with metastatic colorectal cancer.
How similar studies have performed: Previous research has shown promise in using targeted nanoparticle delivery systems for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Vermillion, United States
- University of South Dakota — Vermillion, United States (Active)
Researchers
- Principal investigator: Rezvani, Khosrow Samuel — University of South Dakota
- Study coordinator: Rezvani, Khosrow Samuel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.